Washington, DC (UroToday.com) During the bladder cancer session at the Society of Urologic Oncology Meeting on Thursday, December 5 th, Dr. Colin Dinney presented the results of a phase III clinical ...

(UroToday.com) The 2024 ASTRO annual meeting included a late-breaking abstract session, featuring a presentation by Dr. Ana Kiess discussing outcomes of the RAVENS phase 2 randomized trial assessing ...

(UroToday.com) The 2024 ASTRO annual meeting included a session on the management of small-cell neuroendocrine tumors of the genitourinary tract, featuring a presentation by Dr. Nima Almassi ...

(UroToday.com) The 2024 IBCN annual meeting included a session on advancements in circulating biomarkers, featuring a presentation by Dr. Priyanka Yolmo discussing BCG-induced B cell responses in ...

However, patients with contraindications to chemotherapy from coexisting morbidities are ineligible to receive this therapy and thus have restricted therapeutic options. As our understanding of ...

(UroToday.com) The 2024 American Urological Association (AUA) annual meeting held in San Antonio, TX was host to the advanced prostate cancer moderated poster session. Dr. Ryuma Tanaka presented the ...

(UroToday.com) The 2024 American Urological Association (AUA) Annual Meeting held in San Antonio, TX between May 3 rd and 6 th, 2024 was host to an advanced prostate cancer moderated poster session.

(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting’s included a session on biomarkers and salvage radiotherapy and discussion by Dr. Alan Dal Pra regarding ...

Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our ...

United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence ...